Study of radiolabeled indium-111 and yttrium-90 ibritumomab tiuxetan in primary central nervous system lymphoma

Cancer. 2007 Dec 1;110(11):2528-34. doi: 10.1002/cncr.23077.


Background: Therapeutic options for refractory or recurrent primary central nervous system lymphoma (PCNSL) are limited. The blood-brain barrier makes many agents used in systemic lymphomas ineffective in CNS lymphomas. The objective of this study was to determine whether intravenous radioimmunotherapy using anti-CD20 antibody can be delivered to PCNSL.

Methods: This was a single-institution prospective study. Indium-111 ibritumomab tiuxetan was used for imaging and dosimetry. Yttrium-90 ibritumomab tiuxetan at doses of 0.3 to 0.4 mCi/kg were subsequently given for the treatment of recurrent or refractory PCNSL. 111In data were used to estimate radiation doses to lesions delivered by 90Y ibritumomab tiuxetan therapy.

Results: Six patients (4 men, 2 women) with a median age of 60 years and median Karnofsky performance status of 70 received both indium-111 and yttrium-90 ibritumomab tiuxetan. The median absorbed dose delivered to the CNS lymphoma was 701 cGy compared with 70 cGy to normal brain. The median progression-free and overall survival times were 6.8 weeks and 14.3 weeks, respectively.

Conclusions: The results from this study suggest that it may be feasible to deliver radiolabeled monoclonal anti-CD20 antibodies as a component of therapy for PCNSL.

Publication types

  • Clinical Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aged
  • Central Nervous System Neoplasms / radiotherapy*
  • Disease-Free Survival
  • Female
  • Humans
  • Indium Radioisotopes / therapeutic use*
  • Male
  • Middle Aged
  • Radioimmunotherapy*
  • Radiotherapy Dosage
  • Recurrence
  • Survival Rate
  • Yttrium Radioisotopes / adverse effects
  • Yttrium Radioisotopes / therapeutic use*


  • Indium Radioisotopes
  • Yttrium Radioisotopes